• Improving on "Natural" Rodent Antibodies
• 26 min
  1. The immunogenicity problem in antibody therapy

  • Prof. Herman Waldmann
• 32 min
  2. Antibodies by protein engineering

  • Prof. Sir Gregory Winter
• 60 min
  3. The generation of diversity in antibody genes

  • Prof. Michael Neuberger
• 51 min
  4. Innate immunity to retroelements by human AID/APOBEC3 proteins

  • Prof. Reuben Harris
• 36 min
  5. Fc receptors and antibody effector functions

  • Dr. Mike Clark
• 57 min
  6. Antibody engineering of Fc effector functions

  • Dr. Mike Clark
• 35 min
  7. Antibody engineering: beginnings to bispecifics and beyond

  • Dr. Ian Wilkinson
• Antibodies in Cancer Therapy
• 41 min
  8. Monoclonal antibodies and the ErbB system in human cancer

  • Prof. Mark Greene
• 71 min
  9. Checkpoint blockade in cancer immunotherapy

  • Prof. James Allison
• 45 min
  10. Monoclonal antibodies in haemato-oncology

  • Prof. Mark Cragg
• Diagnostic Antibodies
• 46 min
  11. Monitoring therapy with antibodies

  • Dr. Geoffrey Hale
• Cell Surface Glycoproteins on Cells of the Immune System
• 38 min
  12. Cell surface glycoproteins on cells of the immune system

  • Prof. Neil Barclay
• Antibodies as Immunosuppressants
• 29 min
  13. Monoclonal antibodies to induce therapeutic immunological tolerance

  • Prof. Herman Waldmann
• 29 min
  14. Antibodies to control or prevent type 1 diabetes

  • Dr. Robert Hilbrands
• 48 min
  15. Antibody therapy of multiple sclerosis

  • Dr. Alasdair Coles
  • Prof. Alastair Compston
• 42 min
  16. Monoclonal antibodies in the management of rheumatoid arthritis

  • Prof. John Isaacs
• 40 min
  17. Modern management of rheumatoid arthritis - with a focus on biologic therapies

  • Prof. John Isaacs
• 30 min
  18. Tolerance induction to clotting factors with monoclonal antibodies

  • Prof. Luis Graca
• Archived Lectures *These may not cover the latest advances in the field
• 26 min
  19. Alemtuzumab (Campath-1H) in therapy of CLL

  • Prof. Kanti Rai
• 71 min
  20. VEGF inhibitors for anti-angiogenic therapy

  • Prof. Kari Alitalo
  • Dr. Bronislaw Pytowski
• 26 min
  21. Human antibodies produced in mice

  • Dr. Marianne Bruggemann
• 52 min
  22. New strategies to prevent transplant rejection: from molecules to mice to monkeys to man

  • Prof. Christian Larsen
• 55 min
  23. CD20 antibodies in the targeting of B-cell malignancies and autoimmunity

  • Prof. Thomas Tedder
• 45 min
  24. Anti-IL-2 receptor antibodies as models for cancer therapy

  • Prof. Thomas Waldmann
• 58 min
  25. Anti TNF therapy in rheumatoid arthritis

  • Prof. Marc Feldmann
• 36 min
  26. Novel immunotherapeutic proteins: immunoligand

  • Prof. Terry Strom
• 21 min
  27. Diagnostic immunohistopathology

  • Prof. David Mason
• 56 min
  28. Antibodies in the control of type I diabetes

  • Prof. Lucienne Chatenoud
• 43 min
  29. The challenge of targeting toxins to tumors

  • Prof. Ben Seon
• 38 min
  30. Antibody depletion therapy in transplantation: implications for tolerance

  • Prof. Laurence Turka
• 36 min
  31. Antibodies as anti-virals

  • Prof. Dennis Burton

Printable Handouts

PDF

Navigable Slide Index

1. Introduction
2. TNF: history
3. Why look for cytokines in rheumatoid arthritis?
4. The concept
5. Restimulation of autoantigen reactive T cells
6. Testing the concept: mediators
7. Many cytokines are produced in RS
8. Prolonged synthesis of IL-1-alpha in RS
9. Analysis of cytokine regulation
10. Cytokine cascade in rheumatoid arthritis
11. Cytokine cascade is physiological
12. Protection of joints in an animal model of RA
13. Rationale for anti-TNF-alpha therapy in RA
14. From bench to bedside
15. Remicade(R) (infliximab)
16. Open-label treatment with infliximab in RA
17. Randomised, placebo-controlled trial of infliximab
18. Evidence of efficacy of repeated infliximab therapy
19. Combination therapy - anti-TNF plus anti-CD4
20. Paulus 50% responses to infliximab
21. Rational of combination infliximab and MTX
22. Attract: sustained prevention of structural damage
23. Reversal of structural damage
24. Effectiveness of etanercept-MTX combination
25. Summary of anti-TNF therapy in RA
26. Antibody based therapeutic proteins
27. Adalimumab+MTX: sustained efficacy over 5 years
28. 7 years of etanercept therapy
29. Verifying mechanism of action in phase II useful
30. TNF-alpha dependent cytokine cascade in vivo
31. Other cytokines down regulated also
32. TNF is the body's fire alarm
33. TNF-alpha blockade and inflammatory cell traffic
34. Reduced PMN trafficking after infliximab therapy
35. Chronic inflamation diseases respond to anti-TNF
36. TNF is a good target in many chronic diseases
37. Reduced angiogenesis after anti-TNF
38. Cytokine washout with infliximab
39. Nothing is perfect: problems
40. Safety problems of TNF blockade
41. Early treatment is more effective
42. Prolonged reduction in disease activity
43. Impact on medicine and research
44. Impact on pharmaceutical industry
45. Acknowledgements (1)
46. Acknowledgements (2)
47. Acknowledgements (3)
48. Acknowledgements: funding

Topics Covered

• Immunological basis of rheumatoid arthritis (RA)
• Up-regulated cytokine expression is of major importance in RA
• Analysis of the disordered regulation shows that TNF blockade restored normal cytokine and destructive molecule levels and thus defined TNF as a therapeutic target
• Animal models of arthritis
• Clinical trials
• TNF has major input into leucocyte recruitment, it is thus the body's fire alarm
• TNF blockade and Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriasis, psoriatic arthritis and juvenile RA
• This represents the first major use for monoclonal antibodies in chronic diseases

Links

Series:

• Monoclonal Antibodies as Therapeutic Agents

Categories:

• Clinical Practice
• Immunology

Therapeutic Areas:

• Immunology & Inflammation

Talk Citation

Publication History

• Published on October 1, 2007
• Archived on June 13, 2019

Financial Disclosures

• Prof. Marc Feldmann has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.